Physician profile
Peter K Webb
NPI 1023030582
$3,813.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $102 · 2021: $1,139 · 2022: $1,039.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $660.00 | 2019 | |
| Abbvie INC. | $585.87 | 2019-2022 | |
| Janssen Biotech, INC. | $348.51 | 2019-2022 | |
| Pfizer INC. | $341.62 | 2019-2021 | |
| Leo Pharma INC. | $320.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $270.49 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $228.80 | 2019-2022 | |
| Ucb, INC. | $196.02 | 2021-2022 | |
| Genzyme Corporation | $181.43 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $172.57 | 2019-2021 | |
| Lilly USA, LLC | $132.90 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.65 | 2019-2021 | |
| Incyte Corporation | $72.89 | 2022 | |
| Allergan, INC. | $45.25 | 2021-2022 | |
| Amgen INC. | $33.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $32.66 | 2021 | |
| Almirall LLC | $25.48 | 2019 | |
| Aclaris Therapeutics, INC. | $22.39 | 2019 | |
| Dermira, INC. | $18.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.